The KEYNOTE-054 trial compared pembrolizumab and placebo in resected stage IIIA/B/C melanoma patients and showed remarkable improvement in the pembrolizumab group in both RFS (HR 0.57; CI 98.4%, 0.43–0.74; p < 0.0001) and DMFS (HR 0.60; 95% CI 0.49–0.73, p < 0.0001), irrespective of the PD-L1 status [17]. Here, CD274 is linked to melanoma.